FERAHEME demonstrated non-inferior efficacy in patients with and without chronic kidney disease (CKD)¹

IDA TRIAL 2
FERAHEME was non-inferior to Venofer^® (iron sucrose) in raising Hgb levels ≥2.0 g/dL at any time from baseline to Week 5^2*

Proportion of patients with Hgb increase of ≥2.0 g/dL at any time from baseline to Week 5^1,2

FERAHEME met the predefined criteria for non-inferiority to Venofer^®.²

*Venofer^® is an iron replacement product indicated for the treatment of iron deficiency anemia in patients with CKD.⁴

FERAHEME was non-inferior to Venofer^® (iron sucrose) in mean Hgb rise from baseline^2,5

Mean change in Hgb from baseline to Week 5^2,5†

• Mean change in Hgb from baseline to Week 5 was 2.9±1.6 g/dL for FERAHEME-treated patients and 2.7±1.3 g/dL for Venofer^®-treated patients (treatment difference=0.3 g/dL [95% CI, 0.06 to 0.52], non-inferiority margin: -0.5 g/dL)^1,5

^†n values represent the intent-to-treat population.

CI=confidence interval; Hgb=hemoglobin; IDA=iron deficiency anemia.

back to top

CKD TRIAL
In a non-inferiority study, FERAHEME demonstrated comparable efficacy with Venofer^® (iron sucrose) in iron deficiency anemia patients with chronic kidney disease (CKD)³

The CKD Trial included both dialysis-dependent and non-dialysis-dependent patients¹

Mean change in Hgb from baseline to Week 5³

Error bars represent 95% CI.

• Comparable increases in Hgb were achieved in both treatment groups from baseline to Week 5³

Primary efficacy endpoint: mean change in Hgb from baseline to Week 5^1,3

Select Important Safety Information: The most common adverse reactions (≥2%) are diarrhea, headache, nausea, dizziness, hypotension, constipation, and peripheral edema.

CI=confidence interval; Hgb=hemoglobin; IDA=iron deficiency anemia.

back to top